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Prevalence of rheumatoid arthritis (RA) varies between 0.3 and 0.8% in European countries. [1] Joint invasion and destruction are mainly mediated by inflammatory cells, cytokines and proteolytic enzymes. The heterogeneity of pathological manifestations, disease course, and response to treatments suggests that several subtypes of RA exist, especially at a molecular level.
Early referral, diagnosis and initiation of treatments to control tissue damage and structural progression are highly recommended, considering the disease's high propensity towards joint destruction, even during periods of clinical remission. [2] Although classical treatments are still used [3, 4] , a radical new approach to RA treatment is now available with the use of the biological therapies, such as tumor necrosis factor α (TNFα) inhibitors (etanercept, infliximab, adalimumab), anti-CD20 antibodies (rituximab), interleukin-1 (IL-1) receptor antagonists (anakinra) and an inhibitor of T lymphocyte costimulation (abatacept). Almost 70% of treated patients respond to these therapies, but for unknown reasons, approximately one-third of RA patients do not respond [5] . Indeed, the currently used markers reflecting bone and cartilage turnover [6] are few and inaccurate, and no predictive factor of treatment resistance has been identified. Discovery of biomarkers for diagnosis, prognosis and disease monitoring [7] is necessary.
In order to identify proteins predictive of a treatment response, we chose to study the plasma proteome (i.e. the whole protein content) of RA patients by the technology SELDI-TOF-MS (Surface Enhanced Laser Desorption/Ionization -Time Of Flight Mass Spectrometry) developed by Ciphergen Biosystems, Inc.. [8, 9] This method has allowed characterization of numerous biomarkers for many diseases [10] [11] [12] , particularly cancer. [13] [14] [15] [16] Concerning RA, a first SELDI-based study on 12 synovial fluid samples characterized an RA biomarker absent in osteoarthritis patients, the pro-inflammatory S100A8 protein. [17] More recently the same protein was identified in a larger survey comparing serum protein profiles of RA and non-inflammatory control samples. [18] inserm-00382264, version 1 -2 Jun 2009 4 In our study, we used this SELDI-TOF-MS technology to characterize biomarkers predictive of an anti-TNFα therapy response in RA patients. Protein profiles were performed on plasma specimens taken prior to the start of infliximab treatment, from patients that were further evaluated as non-responders (ACR 20 negative) or responders (ACR 70 positive) to the therapy. Several biomarkers were isolated and were highly correlated with the infliximab response both independently or when associated in a decision tree algorithm. Moreover, corresponding proteins were identified using classical biochemistry techniques.
PATIENTS AND METHODS

Patients and study protocol
Patients with a RA diagnosis according to ACR (American College of Rheumatology) criteria were recruited in four university hospitals from the Rhône-Alpes area. All patients had disease duration of at least 6 months, had never received anti-TNFα therapy before inclusion and had no active or latent bacterial, fungal or viral infection at the time of enrolment. Blood was withdrawn on a spray-coated K 2 EDTA tube before the first infliximab infusion and plasma aliquots were stored at -80°C. Patients then received the same infliximab treatment as previously described [19] Incubation and washing steps were performed as previously described, using the IMAC3 buffer with (first two washes) or without Triton X100 (last two washes). Then 0.8 µl of saturated sinapinic acid in 0.5% trifluoroacetic acid, 50% acetonitrile was applied twice on each spot and chips were analyzed on the ProteinChip ® reader (model PBSII). Mass data processing was performed with the Ciphergen ProteinChip ® software 3.1 and intensities, (height from baseline), of characterized proteins were compared in each group using the Mann-Whitney Utest. ROC (Receiver Operating Characteristic) curve analyses were performed to measure the diagnostic potential of each biomarker and correlations between variables (biomarkers and clinical data) were evaluated using the Spearman rank test. Finally, CART (Classification and
Regression Tree) analysis allowed data classification in a tree-like structured decision diagram. [21] inserm-00382264, version 1 -2 Jun 2009
Protein purification and identification
Apolipoprotein A-I was purified from 300 µl of responder plasma by protein precipitation with 50% ammonium sulfate. After centrifugation at 14000 g for 10 min, 5 µl of supernatant (6.35 µg) was loaded on a 15% SDS-PAGE gel which was further stained with Coomassie blue R-250. The only band revealed at about 28 kDa was excised from the gel, trypsin-digested and sequenced by LC-MSMS (liquid chromatography-tandem mass spectrometry).
Platelet factor 4 (PF4) was purified from 5.2 ml of non-responder plasma on a cobalt-based affinity resin. After washings, the matrix-bound proteins were desorbed with 6 ml PBS 1X containing 20 mM imidazole and 0.5 M NaCl. This specific eluate was dialyzed overnight in distilled water, lyophilized and the resuspended powder was finally loaded on an 18% SDS-PAGE gel. A thick Coomassie blue R-250 stained band between 6 kDa and 14 kDa was sequenced by LC-MSMS as previously described. As results were not conclusive, we set up an ELISA for platelet factor 4 in order to deplete the column specific eluate from the 7,769 Da biomarker. Then 100 µl of eluate diluted twice in 2% bovine serum albumin (BSA) was incubated on a 96-well plate for 2 h at room temperature in wells previously coated with 1, 2 or 10 µg of monoclonal anti-human PF4 antibody (R&D Systems, Lille, France). Next 2 µl of supernatant was loaded on a normal phase NP20 chip which was analyzed on the ProteinChip ® reader. Results were expressed as a ratio of the intensity of the 7,769 Da peak to the BSA peak value in order to overcome possible loading discrepancies and significance was assessed using the Wilcoxon test.
RESULTS
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Blood protein profiles of RA patients before the start of infliximab treatment
Characteristics of enrolled patients are summarized in table 1. Both populations were similar in terms of patient identity (age and sex), RA characteristics (disease duration, number of swollen and tender joints) and biological parameters such as rheumatoid factor (RF), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), demonstrated that in this panel as well as in general RA population, no classical marker of RA severity and aggressiveness could predict the patient response to an anti-TNFα therapy. (without the first 31 amino acids of the signal peptide) [22, 23] , we tried to deplete the column eluate from the biomarker with a homemade PF4 ELISA. The decrease of the peak intensity in the supernatant after incubation with anti-PF4 antibodies, evaluated on an NP20 array, was
proportional to the increase of the amount of antibodies coated in the wells (fig 4B) , with a significant 44% reduction of the signal for the highest antibody concentration ( fig 4C) . This last experiment formally identified the 7.77 kDa biomarker as platelet factor 4. As previously, this biomarker was not correlated to the clinical parameters.
DISCUSSION
In this study with SELDI-TOF-MS we characterized several biomarkers closely correlated to the response to infliximab therapy in RA patients. Although other clinical and biological parameters such as number of inflamed joints, HLA haplotypes or CRP level, can partially predict treatment efficiency [7] , this is the first time to our knowledge that biomarkers with specificity as high as 87.5% independently and 97.5% when associated in a classification tree, have been determined. Indeed, these prediction characteristics were obtained for the discrimination of two extreme patient groups (ACR 20 negative and ACR 70 positive) and it is likely that specificity and sensitivity of these biomarkers will be lower when used on a more homogeneous RA population. Six biomarkers between 3.86 and 74.07 kDa were isolated on two chromatographic surfaces, suggesting different reactivities of these proteins. The smallest one at 3.86 kDa was characterized on an anion array, meaning that this protein is negatively
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11 charged at pH 7. The other 5 biomarkers isolated on an IMAC-Ni chip have a specific affinity for this metallic ion. Three of these proteins were also recovered in the classification tree built from the IMAC-Ni plasma profile, emphasising their importance in the determination of the infliximab response.
We focused initially on the 28 kDa protein that is overexpressed in the responder population and is also the first node of the decision tree, and we identified it as apolipoprotein A-I.
Apolipoprotein A-I is the major protein component of HDL (High Density Protein) particles and the primary acceptor for cholesterol in extra-hepatic tissues. In RA, several studies have reported a decrease of circulating levels of apolipoprotein A-I and HDL-cholesterol in patients compared to the general population [24] [25] [26] , and concentration of both parameters increases significantly in patients responding to a DMARD (Disease-Modifying Anti-Rheumatic Drug) treatment compared to non-responders. [27] On the other hand, apolipoprotein A-I was highly expressed in inflamed RA synovial tissues particularly in perivascular areas containing infiltrated T cells and macrophages, but was not detected in normal tissue [28] or in the synovium of non-inflammatory RA. [29] Moreover, increased levels of apolipoprotein A-I and cholesterol have been measured in RA synovial fluid. [30] As apolipoprotein A-I was reported to inhibit the synthesis of the major inflammatory cytokines TNFα and interleukin-1β by blocking direct contact between T lymphocytes and monocytes [31] , increased levels of this protein in synovial tissue could modulate inflammation and disease evolution by controlling interactions between immune cells and then cytokine production. [28, 32] This specific function as a "negative" acute phase protein is also emphasised in a study reporting that patients with lower levels of apolipoprotein A-1 develop more systemic inflammatory response syndrome criteria. [33] Finally, it has been recently shown in a retrospective study among blood donors (n=1078) who later developed RA (n=79) that the lipid profile was perturbed at least 10 years prior to the inserm-00382264, version 1 -2 Jun 2009 12 onset of symptoms, especially the HDL-cholesterol value that was significantly decreased. [34] The authors suggested that this specific lipid profile may be favourable to the onset of RA or the presence of a constant high inflammatory state due to low levels of HDL-cholesterol. In our study, we demonstrated that high pre-treatment levels of apolipoprotein A-I were predictive of a good response to infliximab. This increased initial concentration may favour the response to anti-TNFα treatment, via the decrease of chronic inflammation, by inhibiting cytokine release and potentiating the efficiency of therapy in a synergistic way.
The second biomarker we focused on was overexpressed in non-responder patients and was identified as platelet factor 4 (PF4) (or CXCL4). This chemokine specific for platelet α-granules exerts multiple functions in several physiological processes. [35] In RA, several studies reported an increase of PF4 in patient synovial fluid [36, 37] and elevated plasma levels in patients with cutaneous vasculitis. [38] In our study, the increase in plasma PF4 was correlated to a non-response to infliximab, and the same rise was recently shown in sera of Crohns disease patients who had not responded to infliximab therapy. In this proteomic study that investigated the plasma protein profile of RA patients who were either responders or non-responders to infliximab therapy, we identified two biomarkers (apolipoprotein A-I and PF4) that may be key elements for RA treatment monitoring. 
